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Duration of dual antiplatelet 
therapy after drug-eluting stent 
implantation: Meta-analysis of 
large randomised controlled trials
Man-Fung Tsoi1, Ching-Lung Cheung1,2,3,4,5, Tommy Tsang Cheung1,3, Ian Chi-Kei Wong2,3,4, 
Cyrus Rustam Kumana1,7, Hung-Fat Tse3,6,7 & Bernard Man-Yung Cheung1,3,4,7
Patients receive dual antiplatelet therapy (DAPT) for 6–12 months after drug-eluting stents (DES) 
implantation. The efficacy and safety of prolonged DAPT has been questioned. Therefore, we 
performed a meta-analysis on randomised trials comparing different DAPT durations. Literature was 
searched on trials comparing different DAPT durations. For inclusion, reports must report frequency 
of cardiovascular and bleeding events. Ten trials were included. Compared to 12 months, DAPT 
beyond 12 months was associated with fewer myocardial infarctions (OR 0.58 95%CI: 0.40–0.84) and 
stent thrombosis (OR 0.35 95%CI: 0.20–0.62), but more major bleeds (OR 1.60 95%CI: 1.22–2.11) and 
all-cause (OR 1.30 95%CI: 1.02–1.66) mortality. There was no significant alteration in risk of stroke 
(OR 0.93 95%CI: 0.66–1.31) or cardiac (OR 1.12 95%CI: 0.73–1.71) mortality. Compared to less than 
12 months DAPT, 12 months DAPT did not reduce risk of myocardial infarction, stent thrombosis, 
strokes, cardiac or all-cause mortality, but increased the risk of major bleeds (OR 1.60 95%CI: 1.22–
2.11). DAPT beyond 12 months reduce risk of myocardial infarction and stent thrombosis, but there is 
substantial increase in major bleeding risk and all-cause mortality which need to be addressed. DAPT 
beyond 12 months does not appear to alter the risk of stroke.
Coronary artery disease is one of the leading causes of morbidity and mortality in developed and devel-
oping countries. Atheroma in coronary arteries reduces myocardial blood flow, leading to ischaemia 
and angina. Percutaneous coronary intervention is now widely performed in conjunction with medical 
therapy to relieve angina and improve exercise tolerance. After balloon angioplasty, implantation of a 
metallic stent helps to prevent recoil and restenosis. The stents used nowadays are usually coated with a 
polymer that elutes a drug such as sirolimus, paclitaxel, everolimus or zotarolimus to suppress neointimal 
hyperplasia. These drug-eluting stents (DES) delay endothelial healing and may increase the risk of stent 
thrombosis, but this can be reduced by dual antiplatelet therapy (DAPT).
Conventionally, patients receive DAPT for 6–12 months after DES implantation1,2. The efficacy and 
safety of prolonged dual antiplatelet therapy (DAPT) has been questioned. In clinical trials comparing 
different durations of DAPT, divergent results have been observed3–12. In general, DAPT regimes shorter 
than 12 months have not been found to be detrimental, and have the advantage of fewer episodes of major 
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bleeding13,14. However, a low percentage of late stent thrombosis remains a challenge. Recently, several 
clinical trials that examined whether longer periods of DAPT are beneficial have been completed7,9–11. 
There is therefore a need to re-examine, in the light of these new trials, the question of whether DAPT for 
longer than 12 months in patients who have received DES is efficacious and safe compared to DAPT for 
12 months and less than 12 months. We used the powerful technique of meta-analysis to determine any 
reduction in cardiovascular events and any increase in serious adverse events such as bleeding or death.
Methods
We searched for randomised trials comparing different durations of DAPT (aspirin + P2Y12 inhib-
itor) after DES implantation on 18 November 2014. PubMed, EMBASE, Scopus, Cochrane database 
of systematic reviews, recent meta-analyses on the subject, recent cardiology conference abstracts and 
ClinicalTrials.gov were searched using the search term “Dual Antiplatelet therapy”, “Myocardial infarc-
tion”, “Stent thrombosis”, “Stroke”, “Drug Eluting Stent” and “Bleeding”. For inclusion, the report had to 
contain the frequency of cardiovascular and bleeding events. A summary of the search process for the 
trials is shown in Supplementary Fig. 1. The inclusion criteria were (1) articles or abstracts written in 
English; (2) participants had to be aged 18 or older; (3) patients had to be randomized to receive different 
durations of DAPT. Analyses of non-randomized trial subgroups were excluded. Data extraction and 
assessment of bias were performed by two investigators. The trials selected for inclusion were stratified 
into three groups according to the durations of DAPT: (1) > 12 months DAPT vs. 12 months DAPT; (2) 
> 12 months DAPT vs. < 12 months DAPT; and (3) 12 months DAPT vs. < 12 months DAPT.
Efficacy outcomes were the frequency of myocardial infraction, stroke and stent thrombosis. The 
safety outcomes were the rate of cardiac and all-cause mortality, and the frequency of bleeding. The 
meta-analysis was performed using RevMan (version 5.3.4). Odds ratios and 95% confidence intervals 
of each trial and combination of trials were calculated using the random effects model. I2 statistics were 
calculated to evaluate heterogeneity among studies. Sensitivity analysis was undertaken to evaluate the 
effect of the inclusion or exclusion of a trial on the summary odds ratio. Bias in the selection or pub-
lication of studies was assessed using funnel plots, Begg’s, Egger’s and trim-and-fill tests. A P-value of 
< 0.05 was taken to indicate statistical significance. We followed the PRISMA Statement on the reporting 
of meta-analysis.
We calculated the number-needed-to-treat (NNT) to prevent one stent thrombosis and the 
number-needed-to-harm (NNH) for major bleed in the DAPT study as the reciprocal of the change in 
absolute risk, which was the difference in proportion of patients with these events in the two arms of 
the study15. These are expressed as NNT or NNH per year as the length of follow-up was 18 months.
Results
Ten trials were included in the meta-analysis3–12. A summary of their characteristics and the risk of bias 
is shown in Table 1, Supplementary Table S1 and Supplementary Table S2.
Trials comparing 12 months with beyond 12 months of DAPT7,10,11 showed a significant reduction in 
myocardial infarction frequency (OR 0.58 95%CI: 0.40 to 0.84, p = 0.004) (Fig. 1A) and stent thrombosis 
(OR 0.35 95%CI: 0.20 to 0.62, p = 0.0003) (Fig. 2A). There was no significant increase in the risk of stroke 
(OR 0.93 95%CI: 0.66 to 1.31) (Fig. 3A), or cardiac death (OR 1.12 95%CI: 0.73 to 1.71) (Fig. 4A), but 
the risk of all-cause mortality (OR 1.30 95%CI 1.02–1.66) (Fig. 5A) and major bleeding were increased 
(OR 1.60 95%CI: 1.22 to 2.11) (Fig. 6A).
Trials comparing less than 12 months of DAPT with beyond 12 months of DAPT5 and 12 months of 
DAPT with less than 12 months of DAPT3,4,6,8,9,12 showed no significant increase in the risk of myocar-
dial infarction (Fig. 1B), definite or probable stent thrombosis (Fig. 2B), stroke (Fig. 3B), cardiac death 
(Fig. 4B) or all-cause mortality (Fig. 5B), but the risk of major bleeding were increased (Fig. 6B).
There was no significant heterogeneity among the trials on stroke, all-cause mortality, or major bleed-
ing (I2 = 0) in three groups. There was no significant heterogeneity among the trials among the trials in 
the effect on myocardial infarction, stent thrombosis and cardiac death in trials comparing 12 months 
and < 12 months of DAPT, and trials comparing > 12 months and < 12 months of DAPT. There was 
heterogeneity among the trials in the effect on myocardial infarction, stent thrombosis and cardiac death 
in trials comparing 12 months and > 12 months of DAPT (I2 = 38%, 18% and 33% respectively, p = 0.21, 
0.30, 0.22 respectively) (Figs 1A, 2A and 4A). Hence, the trials comparing 12 months and > 12 months 
of DAPT were analysed in sensitivity analysis.
The sensitivity analysis is summarised in Supplementary Table S3, S4 and S5, which shows the effect of 
including and excluding each trial on the summary OR and I2. The heterogeneity in the risk of myocar-
dial infarction (I2 = 35%, p = 0.21) was due to DAPT study; omitting DAPT study reduced I2 to 0% and 
resulted in a non-significant OR. The heterogeneity in the risk of stent thrombosis (I2 = 18%, p = 0.30) was 
due to DAPT and DES-LATE study; omitting either one of the studies reduced I2 to 0%. Omitting DAPT 
study resulted in a non-significant OR while omitting DES-LATE study did not result in non-significant 
OR. The heterogeneity in the risk of cardiac death (I2 = 33%, p = 0.22) was due to DAPT and DES-LATE 
study; omitting either one of the studies reduced I2 to 0 and resulted in a non-significant OR.
Funnel plots of the standard error of the log OR against log OR (Supplementary Figs S2A–S7B) did 
not show any significant bias (Supplementary Table S6), except for major bleeding (Supplementary Fig. 
www.nature.com/scientificreports/
3Scientific RepoRts | 5:13204 | DOi: 10.1038/srep13204
S7B). The two extreme outliers correspond to the ITALIC study. The large ORs were due to the very small 
number of major bleeds among those on placebo (1 and 0 respectively) (Fig. 6).
In the DAPT study, the NNT/year to prevent one stent thrombosis was 160 (95% CI: 116 to 260) and 
the NNH/year for major bleed was 167 (95%CI: 105 to 423).
Discussion
Previous meta-analyses of trials comparing short (≤ 6 months) and long duration (≥ 12 months) DAPT 
have not shown any significant benefits for longer duration treatment; instead, there was significantly 
Study
Number of 
participants Intervention Type of Stent used
Treatment 
durations Primary endpoint(s) Bleeding criteria
RESET 20124
12-month 
group: 1058 
3-month 
group: 1059
12 months clopidorgrel + aspirin 
vs 3 months 
clopidorgrel + aspirin
3-month group: ZES 
12-month group: 
SES, EES, ZES (early 
gen.)
12 months 
vs 3 months
Incidence rate of 
cardiovascular death, 
MI, ST, TVR, or 
bleeding) at 1 year
TIMI
EXCELLENT 20123
12-month 
group: 721 
6-month 
group: 722
12 months clopidorgrel + aspirin 
vs 6 months 
clopidorgrel + aspirin
SES and EES 12 months vs 6 months
Composite of cardiac 
death, MI or major 
bleeding during month 
0–12
TIMI
PRODIGY 20125
24-month 
group: 987 
6-month 
group: 983
24 months clopidorgrel + aspirin 
vs 6 months 
clopidorgrel + aspirin
EES (both early and 
new generation), 
PES and BMS#4
24 months 
vs 6 months
Incidence rate of death 
of any cause, non-fatal 
MI or cerebrovascular 
accident at month 24
TIMI
OPTIMIZE 20136
12-month 
group: 1563 
3-month 
group: 1556
12 months clopidorgrel + aspirin 
vs 3 months 
clopidorgrel + aspirin
ZES 12 months vs 3 months
Composite of all-cause 
death, MI, ST, stroke, 
major bleeding at 
month 12
REPLACE-2, GUSTO
DES-LATE 201410
Continue 
DAPT: 2531 
Discontinue 
DAPT: 2514
12 months aspirin vs 12 months 
aspirin + clopidogrel*
SES, PES, ZES, EES 
and other DES
24 months 
vs 12 
months#1
Composite of death due 
to cardiac death, MI 
and stroke at month 24 
after randomization
TIMI
ARCTIC-Interruption 20147
Continue 
DAPT: 635 
Discontinue 
DAPT: 641
12 months 
Thienopyridine + aspirin vs 12 
months aspirin*
SES, PES, ZES, EES
18–30 
months vs 
12 months
Composite of all-cause 
mortality, MI, stroke, 
ST, urgent Coronary 
revascularization or 
transient ischemic 
attack at month 30
STEEPLE
SECURITY 20148
6-month 
group: 682 
12-month 
group: 717
12 months aspirin + 6 months 
clopidogrel vs 12 months 
clopidogrel
ZES, EES, Nobori 
stent, Biomatrix 
stent, Promus stent
12 months 
vs 6 months
Composite of cardiac 
death, MI, stroke, ST, 
type 3 or 5 bleeding as 
defined in the criteria at 
month 12
BARC
ISAR-SAFE 201412
12-month 
group: 2003 
6-month 
group: 1997
Antiplatelet drug (not specified 
in the presentation) + 6 months 
clopidogrel followed by 6 months 
placebo vs 12 months clopidogrel
SES, PES, ZES, EES, 
BES, Bioresorbable 
EES, BMS, drug-
coated balloon 
and plain balloon 
angioplasty#3
12 months 
vs 6 months
Composite of death, 
MI, ST, stroke, major 
bleeding at month 15
TIMI
ITALIC 20149
24-month 
group: 910 
6-month 
group: 912
24 months aspirin + 24 months 
vs 6 months clopidogrel, 
prasugrel or tricagrlor
ZES
24 months 
vs 6 
months#5
Composite of death, 
MI, emergency TVR at 
month 12
TIMI
DAPT 201411
30-month 
group: 4710 
12-month 
group: 4649
30 months aspirin + 30 months 
Thienopyridine vs 12 months 
Thienopyridine followed by 18 
months placebo
SES, ZES, PES, 
BMS#2
30 months 
vs 12 
months
No. of patients 
with ST and major 
cardiovascular and 
cerebrovascular events 
(including stroke and 
MI) at month 30
BARC, GUSTO
Table 1.  Summary for trial design for studies included in meta-analysis. Abbreviations used in table 1, 
ST: Stent thrombosis; MI: myocardial infraction; TVR: target vessel revascularization; DES: Drug-eluting 
stent; gen.: generation; BES: Biolimus-eluting stent; BMS: Bare metal stent; EES: Everolimus-eluting stent; 
ZES: Zotarolimus-eluting stent; PES: paclitaxel-eluting stent; SES: sirolimus-eluting stent. *Patients in 
ARCTIC-Interruption and DES-LATE Study had previous DAPT. DES-LATE study had cumulative data 
for primary and secondary outcomes in the research article supplement. #1DES-LATE study allowed patient 
enrolment with 1 year or longer after percutaneous coronary intervention. #2DAPT study allowed enrolment 
of patients with BMS but they were not included in statistical analysis. #3In ISAR-SAFE study, the number 
of patients who received BMS, drug-coated balloon and plain balloon angioplasty were 8 (0.4%), 8 (0.4%) 
and 2 (0.1%) for 6-month DAPT; 6 (0.3%), 8 (0.4%) and 2 (0.1%) for 12-month DAPT respectively. #4In 
PRODIGY study, the number of patients who received BMS were 246 (24.9%) for 6-month DAPT; 246 
(25.0%) for 24-month DAPT respectively. #5First year data of ITALIC study has been published.
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Figure 1. (A) The effect of prolonging the duration of dual antiplatelet therapy to more than 12 months 
on frequency of myocardial infarction in patients after drug-eluting stent implantation. (B) The effect of 
shortening the duration of dual antiplatelet therapy to less than 12 months on the frequency of myocardial 
infarction in patients after drug-eluting stent implantation.
Figure 2. (A) The effect of prolonging the duration of dual antiplatelet therapy to more than 12 months on 
frequency of definite or probable stent thrombosis in patients after drug-eluting stent implantation.  
(B) The effect of shortening the duration of dual antiplatelet therapy to less than 12 months on the 
frequency of definite or probable stent thrombosis in patients after drug-eluting stent implantation.
www.nature.com/scientificreports/
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increased frequency of major bleeding13,16. Therefore, many believed that a duration of DAPT shorter 
than 12 months is not significantly inferior in preventing stent thrombosis and myocardial infarction, 
but it would reduce exposure of patients to intense antiplatelet treatment with the resultant risk of 
Figure 3. (A) The effect of prolonging the duration of dual antiplatelet therapy to more than 12 months 
on frequency of stroke in patients after drug-eluting stent implantation. (B) The effect of shortening the 
duration of dual antiplatelet therapy to less than 12 months on frequency of stroke in patients after drug-
eluting stent implantation.
Figure 4. (A) The effect of prolonging the duration of dual antiplatelet therapy to more than 12 months on 
cardiac death rate in patients after drug-eluting stent implantation. (B) The effect of shortening the duration 
of dual antiplatelet therapy to less than 12 months on cardiac death rate in patients after drug-eluting stent 
implantation.
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Figure 5. (A) The effect of prolonging the duration of dual antiplatelet therapy to more than 12 months 
on all-cause mortality rate in patients after drug-eluting stent implantation. (B) The effect of shortening the 
duration of dual antiplatelet therapy to less than 12 months on all-cause mortality rate in patients after drug-
eluting stent implantation.
Figure 6. (A) The effect of prolonging the duration of dual antiplatelet therapy to more than 12 months on 
frequency of major bleeding in patients after drug-eluting stent implantation. (B) The effect of shortening 
the duration of dual antiplatelet therapy to less than 12 months on the frequency of major bleeding in 
patients after drug-eluting stent implantation.
www.nature.com/scientificreports/
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major bleeds. Relatively small trials exploring the possible benefits of extending DAPT to longer than 12 
months did not have sufficient power to show beneficial effects5,7,9,10. The DAPT study was a large trial 
that showed a significant reduction in the number of patient stent thrombosis and myocardial infarction. 
Thus, it confirms the trend towards reduction in these events in the previous trials. However, not only 
was there an expected increase in major bleeding, there was also a trend towards increased mortality11. 
Although a concurrent meta-analysis showed that DAPT in general did not cause excess mortality, the 
results of the DAPT study were surprising and required confirmation17. The present meta-analysis is 
ground-breaking in establishing that DAPT longer than 12 months after DES implantation markedly 
reduces myocardial infarction and stent thrombosis. This finding provides a rationale for considering 
prolonged DAPT in these patients.
However, prolonged DAPT is not without risk. In the DAPT study, for every stent thrombosis pre-
vented, nearly one major bleed occurred11. Thus, clinical judgment is necessary to weigh up the benefits 
and risks in the individual patient, and explain them to the patient in a way that can be understood. In 
this regard, we do not have the equivalent of validated risk scores such as CHA2DS2-VASc and HAS-BLED 
that facilitate decisions to anticoagulate patients with atrial fibrillation14,18. Besides intensive antiplatelet 
therapy, we do not have other effective means of preventing stent thrombosis in procedurally successful 
DES implantations, though there may be ways of reducing the bleeding risk. In the setting of prolonged 
DAPT, it remains to be proven whether careful patient selection based on medical history, helicobacter 
eradication, and prophylaxis with proton pump inhibitor can minimise this risk. The physician should 
now endeavour to do this before denying patients DAPT because of perceived bleeding risks.
As regards mortality, although a recent meta-analysis on DAPT found no significant increase in 
mortality with prolonged treatment17, that meta-analysis did not include ISAR-SAFE or ITALIC. A 
meta-analysis that compared shorter and longer DAPT found a non-significant increase in all-cause mor-
tality19. A meta-analysis using individual patient data did not show any significant increase in all-cause 
mortality, but that might have been due to the availability of individual patient data in only four trials20. 
A more recent meta-analysis showed a 22% increase in all-cause mortality and a 49% increased rate of 
non-cardiac mortality associated with DAPT beyond 12 months21. Our meta-analysis showed similar 
findings. Until we have more data on the safety of DAPT beyond 12 months, the large reduction in 
myocardial infarction brought about by DAPT beyond 12 months has to be weighed against an increased 
risk of major bleeds and mortality. Whether or not major bleeds become life-threatening is influenced 
by the availability and timeliness of the emergency medical care, which can vary from place to place.
The neutral effect of DAPT on stroke rate is interesting. Antiplatelet therapy is expected to reduce 
thrombotic strokes but may increase the rate of haemorraghic strokes or haemorrhagic transformation of 
an ischaemic stroke. More studies are needed to explore this issue. At least, we can conclude that DAPT 
does not increase the risk of stroke.
Before implementing long-term DAPT for DES patients, the limitations of clinical trial evidence must 
not be overlooked. Trials recruit voluntary patients who may be more compliant with treatment. Inclusion 
and exclusion criteria create trial populations that may not be completely representative of patients in the 
real world. Patients with certain co-morbidities and those at high risk of bleeding are excluded. Patients 
with major bleeding in first year of DAPT therapy were excluded in DAPT, ARCTIC-Interruption and 
DES-LATE study. Thus, DAPT was only continued beyond one year in those who could tolerate it in the 
first year. Not all patients would be suitable for DAPT beyond 12 months.
There were also differences among the trials with respect to the types of DES used and the definition 
of myocardial infarction and major bleeding. Different types of DES, especially newer stents, may differ 
in the optimal duration of DAPT. Second generation DESs are known to be as effective as first genera-
tion DESs, but with a lower risk of stent thrombosis22. First generation DESs were used in some of the 
patients in DES-LATE, ARCTIC-Interruption and the DAPT study, but second generation DESs are now 
the main types of stents in clinical use. As the rate of stent thrombosis is low with second generation 
DES, it would be difficult to do a trial with enough stent thrombosis events to analyse; and with a very 
low rate of stent thrombosis, it may not be clinically important to reduce this rate further. However, 
optimal coherence tomography shows that incomplete stent apposition is not uncommon at 12 months 
after implantation of everolimus-eluting stents, a second generation DES23. Even with a biodegradable 
polymer stent, stent thrombosis still occurs after one year24. Therefore, advances in stent technology have 
reduced stent thrombosis but have not eliminated it. In patients with coronary artery atherosclerosis, the 
thrombus causing myocardial infarction need not be at the site of previous stenting. DAPT may therefore 
have benefits beyond its effect on reducing stent thrombosis.
Definitions of major and minor bleeding varied among the trials; different criteria based on clinical 
symptoms, laboratory parameters, or both, were used25. Although the number of major bleeds in the 
trials is open to interpretation, there is little doubt that DAPT carries a higher risk of bleeding.
It should also be remembered that myocardial infarctions in clinical trials were often diagnosed on 
the basis of rises in cardiac troponin or creatine kinase26. These small infarcts might not result in severe 
clinical symptoms or poor prognosis. The prevention of small infarcts may not be a sufficient justification 
for a treatment that increases the risk of major bleeding and death.
In conclusion, this meta-analysis of randomised trials comparing different durations of DAPT after 
DES implantation shows benefits in extending DAPT beyond 12 months, in terms of a lower frequency 
of myocardial infarction and stent thrombosis. There is no significant decrease in cardiac mortality and 
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stroke, but there is an increase in major bleeds and all-cause mortality. DAPT for 12 months or for a 
shorter duration do not differ with respect to efficacy or safety endpoints. Physicians can consider con-
tinuing DAPT beyond 12 months after weighing up the benefits and risks, informing patients fully of 
the increased risk of major bleeding, and taking steps to minimise this risk.
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